{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T05:24:43Z","timestamp":1787030683659,"version":"build-2736575974"},"reference-count":36,"publisher":"Spandidos Publications","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncol Lett"],"DOI":"10.3892\/ol.2024.14451","type":"journal-article","created":{"date-parts":[[2024,5,14]],"date-time":"2024-05-14T06:02:54Z","timestamp":1715666574000},"source":"Crossref","is-referenced-by-count":5,"title":["Regorafenib plus programmed death\u20111 inhibitors vs. regorafenib monotherapy in second\u2011line treatment for advanced hepatocellular carcinoma: A systematic review and meta\u2011analysis"],"prefix":"10.3892","volume":"28","author":[{"given":"Zhao","family":"Li","sequence":"first","affiliation":[{"name":"Department of Hepato\u2011Biliary\u2011Pancreas II, Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan 637000, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Hepato\u2011Biliary\u2011Pancreas II, Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan 637000, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingbing","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Hepato\u2011Biliary\u2011Pancreas II, Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan 637000, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengwei","family":"Leng","sequence":"additional","affiliation":[{"name":"Department of Hepato\u2011Biliary\u2011Pancreas II, Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan 637000, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2249","published-online":{"date-parts":[[2024,5,14]]},"reference":[{"key":"key20240611104447_b1-ol-28-1-14451","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1007\/s11864-023-01098-9","article-title":"Hepatocellular carcinoma: A narrative review on current knowledge and future prospects","volume":"24","author":"Alawyia","year":"2023","journal-title":"Curr Treat Options Oncol"},{"key":"key20240611104447_b2-ol-28-1-14451","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/s41572-020-00240-3","article-title":"Hepatocellular carcinoma","volume":"7","author":"Llovet","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"key20240611104447_b3-ol-28-1-14451","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1016\/S1470-2045(21)00151-0","article-title":"Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): An open-label, randomised, phase 3 trial","volume":"22","author":"Galle","year":"2021","journal-title":"Lancet Oncol"},{"key":"key20240611104447_b4-ol-28-1-14451","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","article-title":"Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: A randomised phase 3 non-inferiority trial","volume":"391","author":"Kudo","year":"2018","journal-title":"Lancet"},{"key":"key20240611104447_b5-ol-28-1-14451","doi-asserted-by":"publisher","first-page":"2943","DOI":"10.21037\/jgo-21-414","article-title":"Second-line treatment with nivolumab, cabozantinib, regorafenib, or best supportive care in patients with advanced hepatocellular carcinoma: Analysis at a Hispanic-majority NCI-designated cancer center","volume":"12","author":"Xia","year":"2021","journal-title":"J Gastrointest Oncol"},{"key":"key20240611104447_b6-ol-28-1-14451","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1002\/ijc.25864","article-title":"Regorafenib (BAY 73\u20134506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity","volume":"129","author":"Wilhelm","year":"2011","journal-title":"Int J Cancer"},{"key":"key20240611104447_b7-ol-28-1-14451","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/S0140-6736(16)32453-9","article-title":"Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): A randomised, double-blind, placebo-controlled, phase 3 trial","volume":"389","author":"Bruix","year":"2017","journal-title":"Lancet"},{"key":"key20240611104447_b8-ol-28-1-14451","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1159\/000515280","article-title":"Clinical outcomes of 2nd- and 3rd-Line regorafenib for advanced hepatocellular carcinoma","volume":"99","author":"Naruto","year":"2021","journal-title":"Oncology"},{"key":"key20240611104447_b9-ol-28-1-14451","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1159\/000448864","article-title":"Recent trends in the management of hepatocellular carcinoma with special emphasis on treatment with Regorafenib and immune checkpoint inhibitors","volume":"34","author":"Kudo","year":"2016","journal-title":"Dig Dis"},{"key":"key20240611104447_b10-ol-28-1-14451","doi-asserted-by":"publisher","first-page":"114254","DOI":"10.1016\/j.biopha.2023.114254","article-title":"Regorafenib enhances anti-tumor efficacy of immune checkpoint inhibitor by regulating IFN-\u03b3\/NSDHL\/SREBP1\/TGF-\u03b21 axis in hepatocellular carcinoma","volume":"159","author":"Xie","year":"2023","journal-title":"Biomed Pharmacother"},{"key":"key20240611104447_b11-ol-28-1-14451","doi-asserted-by":"publisher","first-page":"e001435","DOI":"10.1136\/jitc-2020-001435","article-title":"Regorafenib combined with PD1 blockade increases CD8 T-cell infiltration by inducing CXCL10 expression in hepatocellular carcinoma","volume":"8","author":"Shigeta","year":"2020","journal-title":"J Immunother Cancer"},{"key":"key20240611104447_b12-ol-28-1-14451","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s10238-021-00727-7","article-title":"Second-line treatments for advanced hepatocellular carcinoma: A systematic review and Bayesian network meta-analysis","volume":"22","author":"Solimando","year":"2022","journal-title":"Clin Exp Med"},{"key":"key20240611104447_b13-ol-28-1-14451","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"key20240611104447_b14-ol-28-1-14451","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"key20240611104447_b15-ol-28-1-14451","doi-asserted-by":"publisher","first-page":"157","DOI":"10.2147\/JHC.S353956","article-title":"Regorafenib combined with PD-1 blockade immunotherapy versus Regorafenib as second-line treatment for advanced hepatocellular carcinoma: A multicenter retrospective study","volume":"9","author":"Huang","year":"2022","journal-title":"J Hepatocell Carcinoma"},{"key":"key20240611104447_b16-ol-28-1-14451","doi-asserted-by":"publisher","first-page":"329","DOI":"10.2147\/TCRM.S400079","article-title":"Clinical efficacy and safety of an immune checkpoint inhibitor in combination with regorafenib therapy as second-line regimen for patients with unresectable hepatocellular carcinoma","volume":"19","author":"Li","year":"2023","journal-title":"Ther Clin Risk Manag"},{"key":"key20240611104447_b17-ol-28-1-14451","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.2147\/OTT.S383685","article-title":"Efficacy and safety of Regorafenib with or without PD-1 inhibitors as second-line therapy for advanced hepatocellular carcinoma in real-world clinical practice","volume":"15","author":"Liu","year":"2022","journal-title":"Onco Targets Ther"},{"key":"key20240611104447_b18-ol-28-1-14451","doi-asserted-by":"publisher","first-page":"109","DOI":"10.21037\/atm-22-6614","article-title":"A multi-center retrospective study on the efficacy and safety of regorafenib vs. regorafenib combined with PD-1 inhibitors as a second-line therapy in patients with advanced hepatocellular carcinoma","volume":"11","author":"Yan","year":"2023","journal-title":"Ann Transl Med"},{"key":"key20240611104447_b19-ol-28-1-14451","doi-asserted-by":"publisher","first-page":"109401","DOI":"10.1016\/j.intimp.2022.109401","article-title":"Immunotherapy combination with regorafenib for refractory hepatocellular carcinoma: A real-world study","volume":"113","author":"Tu","year":"2022","journal-title":"Int Immunopharmacol"},{"key":"key20240611104447_b20-ol-28-1-14451","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/s41575-022-00704-9","article-title":"Evolving therapeutic landscape of advanced hepatocellular carcinoma","volume":"20","author":"Yang","year":"2023","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"key20240611104447_b21-ol-28-1-14451","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1016\/S0140-6736(22)01200-4","article-title":"Hepatocellular carcinoma","volume":"400","author":"Vogel","year":"2022","journal-title":"Lancet"},{"key":"key20240611104447_b22-ol-28-1-14451","doi-asserted-by":"publisher","first-page":"101993","DOI":"10.1016\/j.ctrv.2020.101993","article-title":"Evolving role of regorafenib for the treatment of advanced cancers","volume":"86","author":"Grothey","year":"2020","journal-title":"Cancer Treat Rev"},{"key":"key20240611104447_b23-ol-28-1-14451","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/S0140-6736(12)61900-X","article-title":"Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): An international, multicentre, randomised, placebo-controlled, phase 3 trial","volume":"381","author":"Grothey","year":"2013","journal-title":"Lancet"},{"key":"key20240611104447_b24-ol-28-1-14451","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1007\/s40265-018-0932-4","article-title":"Regorafenib: A review in hepatocellular carcinoma","volume":"78","author":"Heo","year":"2018","journal-title":"Drugs"},{"key":"key20240611104447_b25-ol-28-1-14451","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1016\/S1470-2045(18)30351-6","article-title":"Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): A non-randomised, open-label phase 2 trial","volume":"19","author":"Zhu","year":"2018","journal-title":"Lancet Oncol"},{"key":"key20240611104447_b26-ol-28-1-14451","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1200\/JCO.19.01307","article-title":"Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: A randomized, double-blind, phase III trial","volume":"38","author":"Finn","year":"2020","journal-title":"J Clin Oncol"},{"key":"key20240611104447_b27-ol-28-1-14451","doi-asserted-by":"publisher","first-page":"17562848211016959","DOI":"10.1177\/17562848211016959","article-title":"Experience with regorafenib in the treatment of hepatocellular carcinoma","volume":"14","author":"Granito","year":"2021","journal-title":"Therap Adv Gastroenterol"},{"key":"key20240611104447_b28-ol-28-1-14451","doi-asserted-by":"publisher","first-page":"4530","DOI":"10.1158\/1078-0432.CCR-18-2840","article-title":"Regorafenib promotes antitumor immunity via inhibiting PD-L1 and IDO1 expression in melanoma","volume":"25","author":"Wu","year":"2019","journal-title":"Clin Cancer Res"},{"key":"key20240611104447_b29-ol-28-1-14451","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1080\/14737140.2023.2181162","article-title":"TKIs in combination with immunotherapy for hepatocellular carcinoma","volume":"23","author":"Stefanini","year":"2023","journal-title":"Expert Rev Anticancer Ther"},{"key":"key20240611104447_b30-ol-28-1-14451","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1038\/s41591-024-02824-y","article-title":"Regorafenib plus nivolumab in unresectable hepatocellular carcinoma: The phase 2 RENOBATE trial","volume":"30","author":"Kim","year":"2024","journal-title":"Nat Med"},{"key":"key20240611104447_b31-ol-28-1-14451","doi-asserted-by":"publisher","first-page":"949","DOI":"10.2147\/JHC.S415941","article-title":"Simultaneous and sequential use of molecular targeted agents plus immune checkpoint inhibitors for advanced hepatocellular carcinoma: A real-world practice in China","volume":"10","author":"Li","year":"2023","journal-title":"J Hepatocell Carcinoma"},{"key":"key20240611104447_b32-ol-28-1-14451","first-page":"321","article-title":"Lenvatinib plus immune checkpoint inhibitors versus Lenvatinib monotherapy as treatment for advanced hepatocellular carcinoma: A meta-analysis","volume":"16","author":"Yu","year":"2023","journal-title":"Int J Clin Exp Pathol"},{"key":"key20240611104447_b33-ol-28-1-14451","doi-asserted-by":"publisher","first-page":"2549","DOI":"10.21037\/jgo-23-590","article-title":"Efficacy and safety of regorafenib in combination with immune checkpoint inhibitor therapy as second-line and third-line regimen for patients with advanced hepatocellular carcinoma: A retrospective study","volume":"14","author":"Zhao","year":"2023","journal-title":"J Gastrointest Oncol"},{"key":"key20240611104447_b34-ol-28-1-14451","article-title":"Regorafenib Plus Sintilimab vs. Regorafenib as the Second-line Treatment for HCC","author":"Nct"},{"key":"key20240611104447_b35-ol-28-1-14451","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1007\/s10637-018-0707-5","article-title":"Multicenter retrospective analysis of the safety and efficacy of regorafenib after progression on sorafenib in Korean patients with hepatocellular carcinoma","volume":"37","author":"Yoo","year":"2019","journal-title":"Invest New Drugs"},{"key":"key20240611104447_b36-ol-28-1-14451","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1038\/s41571-021-00573-2","article-title":"Immunotherapies for hepatocellular carcinoma","volume":"19","author":"Llovet","year":"2022","journal-title":"Nat Rev Clin Oncol"}],"container-title":["Oncology Letters"],"original-title":[],"deposited":{"date-parts":[[2024,6,11]],"date-time":"2024-06-11T03:51:35Z","timestamp":1718077895000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/ol.2024.14451"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,14]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,5,14]]}},"URL":"https:\/\/doi.org\/10.3892\/ol.2024.14451","relation":{},"ISSN":["1792-1074","1792-1082"],"issn-type":[{"value":"1792-1074","type":"print"},{"value":"1792-1082","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,14]]},"article-number":"318"}}